CTLA4 and hepatocellular carcinoma: Tremelimumab, a monoclonal antibody targeting CTLA-4, shows significant potential for patients with advanced HCC stemming from HCV-induced liver cirrhosis, as evidenced by the study conducted by Sangro B. et al. [101].